Cargando…
Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease
Since inflammatory bowel disease (IBD) patients were excluded from vaccine authorization studies, limited knowledge exists regarding perceptions and unfavorable effects of COVID-19 vaccination in this group. We aimed to investigate the real-world use and adverse events (AEs) of COVID-19 vaccines in...
Autores principales: | Orfanoudaki, Eleni, Zacharopoulou, Eirini, Kitsou, Vassiliki, Karmiris, Konstantinos, Theodoropoulou, Angeliki, Mantzaris, Gerassimos J., Tzouvala, Maria, Michopoulos, Spyridon, Zampeli, Evanthia, Michalopoulos, Georgios, Karatzas, Pantelis, Viazis, Nikos, Liatsos, Christos, Bamias, Giorgos, Koutroubakis, Ioannis E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836981/ https://www.ncbi.nlm.nih.gov/pubmed/35160092 http://dx.doi.org/10.3390/jcm11030641 |
Ejemplares similares
-
Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022) -
Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022) -
The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021) -
Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
por: Bamias, Giorgos, et al.
Publicado: (2021) -
The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
por: Viazis, N., et al.
Publicado: (2023)